| |
Everest Group evaluated provider capabilities across five areas: marketing support & effectiveness; pricing, reimbursement & market access; salesforce effectiveness; contract management; and product support services. Read the full assessment now. 
|
|
|
Thursday, June 8, 2023 | 11am ET / 8am PT In this webinar, we will explore how predictive capabilities enabled by AI can inform which patients are at risk for poor medication behaviors, identify the best interventions for each patient, and create one-to-one experiences in support programs that improve initiation, adherence, and health outcomes. Register now to learn more. 
|
|
| By Gabrielle Masson The departures of 2021's three highest paid R&D executives from Big Pharma threw a curveball at our annual list, prompting us to trim the feature down to five leaders. |
|
|
|
| San Diego, CA |  |
|
|
By Kevin Dunleavy In the rush to supply prescriptions of Novo Nordisk’s popular diabetes and weight loss meds, some pharmacies are making unauthorized versions of Ozempic and Wegovy, the FDA warned on Tuesday. Some compounding pharmacies are using unauthorized versions of semaglutide, according to the FDA. |
By Andrea Park Despite multiple attempts to put off the start of her 135-month prison sentence after being found guilty on four counts of defrauding investors in blood-testing startup Theranos, the time has come for Elizabeth Holmes to report to prison. |
By Angus Liu Before the annual ASCO meeting, Fierce Pharma gathered expectations for two important early-stage cancer studies from oncology leaders at Penn Medicine and MD Anderson Cancer Center plus analysts at SVB Securities and Cowen. |
By James Waldron Roche's faith in TIGIT may have finally been rewarded, as tiragolumab shows signs of efficacy in liver cancer. |
By Teresa Carey This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
By Gabrielle Masson When it rains, it pours, an old adage that Rain Oncology hasn’t been able to shelter from. After a phase 3 fail, the precision oncology biotech is saying farewell to its chief medical officer, halting programs and laying off 65% of its workforce. |
By Joseph Keenan UCB Pharma, a Belgium-based biopharma company, has been slapped with a Form 483 from the FDA following an inspection that uncovered issues with its quality control unit and product storage. |
By Andrea Park In spite of a wave of news reports suggesting that more delays were on the horizon, almost exactly six months after Elon Musk said his neurotech company Neuralink was half a year away from beginning human trials of its flagship brain implant, the company has achieved that goal. |
By Kevin Dunleavy Eli Lilly has agreed to pay $13.5 million to end a six-year, class-action lawsuit that alleged the company overpriced its insulin. As part of the settlement, Lilly has agreed to cap out-of-pocket cost its insulin at $35 per month for four years. |
By Nick Paul Taylor Pfizer is looming large in Novo Nordisk’s rearview mirror. Weeks after seeing its rival for the hemophilia market stumble, Pfizer has reported phase 3 data that suggest its candidate is competitive and position it to file for approval in the coming months. |
By Zoey Becker As drug shortages persist nationwide, the director of the FDA Oncology Center of Excellence, Richard Pazdur, M.D., talked about the root cause of the problem and the agency's response. One cause, he says, is that manufacturers haven't invested enough to build capacity. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, Jun 14, 2023 | 10:00am ET / 7:00am PT Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. Register now. 
|
|
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Executive Summary Traditional real-world data isn’t truly from the real world – it’s from the clinical world, and it’s missing a big part of neuro patients’ stories. Sponsored by: Evidation Health |
Whitepaper Building a Sustainable Blueprint for a Holistic Market Access Strategy Sponsored by: EVERSANA® |
Whitepaper Modern software development and its impact on addressing clinical trial complexity. Sponsored by: YPrime |
Whitepaper Drive brand growth with proven digital strategies to accelerate and optimize all lifecycle stages including drug discovery, launch, maturity and LoE. Sponsored by: LiveWorld full-service digital agency with deep social expertise |
Research There’s a $70 billion growth opportunity for pharma and medtech in transitioning care from the hospital to home. Read our latest report to find out how we can create better patient outcomes and drive health equity. Sponsored by: PA Consulting |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Discover the new gold standard for gene therapy protein expression potency measurements. Sponsored by: Bio-Techne |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
Whitepaper This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
